A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Exclusion Criteria

• •Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
• •Has presence of gastrointestinal condition, e.g. malabsorption, that might affect the adsorption of study intervention.
• •Has a history of pituitary dysfunction.
• •Has poorly controlled diabetes mellitus.
• •Has active or unstable cardio/cerebro-vascular disease, including thromboembolic events.
• •Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 4 weeks of the date of allocation.
• •Has received an anticancer monoclonal antibody (mAb) within 4 weeks of allocation, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of allocation.
• •Received prior systemic anticancer therapy including investigational agents within 4 weeks before the date of allocation.
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any form of immunosuppressive therapy within 7 days prior to the start of study intervention.
• •Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years.
• •Has a history of or current human immunodeficiency virus (HIV) infection.
• •Has a concurrent Hepatitis B or Hepatitis C virus infection.
• •Has a history of allogenic tissue or solid organ transplant.